Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/the-new-england-journal-of-medicine/management-of-multiple-sclerosis-kYxplEbzzV
References (82)
-
M. Girard, P. Duquette, W. Sibley (1993)
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.Neurology
-
K. Johnson, B. Brooks, Jeffrey Cohen, C. Ford, Jill Goldstein, R. Lisak, L. Myers, H. Panitch, J. Rose, R. Schiffer, T. Vollmer, L. Weiner, J. Wolinsky (1995)
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 45
-
R. Mandler, L. Davis, D. Jeffery, M. Kornfeld (1993)
Devic's neuromyelitis optica: A clinicopathological study of 8 patientsAnnals of Neurology, 34
-
B. Weinshenker, G. Rice, J. Noseworthy, W. Carriere, J. Baskerville, G. Ebers (1991)
The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.Brain : a journal of neurology, 114 ( Pt 2)
-
L. Bö, S. Mörk, P. Kong, H. Nyland, C. Pardo, B. Trapp (1994)
Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesionsJournal of Neuroimmunology, 51
-
K. Wucherpfennig, J. Strominger (1995)
Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic proteinCell, 80
-
H. McFarland, J. Frank, P. Albert, Mary Smith, Roland Martin, Jonathan Harris, N. Patronas, H. Maloni, D. McFarlin (1992)
Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosisAnnals of Neurology, 32
-
D. Goodkin, S. Plencner, J. Palmer-Saxerud, M. Teetzen, Doris Hertsgaard (1987)
Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy.Archives of neurology, 44 8
-
J. Haines, M. Ter-Minassian, A. Bazyk, J. Gusella, D. Kim, H. Terwedow, M. PericakVance, J. Rimmler, C. Haynes, A. Roses, A. Lee, B. Shaner, M. Menold, E. Seboun, R. Fitoussi, C. Gartioux, C. Reyes, F. Ribiérre, G. Gyapay, J. Weissenbach, S. Hauser, D. Goodkin, R. Lincoln, K. Usuku, A. García‐Merino, N. Gatto, S. Young, J. Oksenberg (1996)
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complexNature Genetics, 13
-
N. Larocca, P. Ritvo, Deborah Miller, J. Fischer, H. Andrews, D. Paty (1996)
“Quality of Life” Assessment in Multiple Sclerosis Clinical Trials: Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design -
R. Herndon (1994)
Treatment of Multiple Sclerosis: Trial Design, Results, and Future PerspectivesJAMA Neurology, 51
-
V. Tuohy, Min Yu, B. Weinstock-Guttman, R. Kinkel (1997)
Diversity and plasticity of self recognition during the development of multiple sclerosis.The Journal of clinical investigation, 99 7
-
D. Gold, R. Smith, Anna Golding, E. Morgan, Tanya Dafashy, J. Nelson, Larry Smith, Joji Diveley, J. Laxer, S. Richieri, D. Carlo, S. Brostoff, Darcy Wilson (1997)
Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptideJournal of Neuroimmunology, 76
-
Roy Beck, P. Cleary, Malcolm Anderson, J. Keltner, W. Shults, D. Kaufman, E. Buckley, J. Corbett, M. Kupersmith, Neil Miller, P. Savino, J. Guy, J. Trobe, J. Mccrary, Craig Smith, G. Chrousos, H. Thompson, Barrett Katz, M. Brodsky, J. Goodwin, Constance Atwell (1992)
A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic NeuritisThe New England Journal of Medicine, 326
-
U. Traugott, E. Reinherz, C. Raine (1983)
Multiple sclerosis Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different agesJournal of Neuroimmunology, 4
-
G. Ellison (1996)
Recent Advances and Future Challenges in Multiple Sclerosis Clinical Trial Design -
R. Rudick, D. Goodkin, L. Jacobs, D. Cookfair, R. Herndon, J. Richert, A. Salazar, J. Fischer, C. Granger, J. Simon, J. Alam, N. Simonian, M. Campion, D. Bartoszak, D. Bourdette, J. Braiman, C. Brownscheidle, M. Coats, S. Cohan, D. Dougherty, R. Kinkel, M. Mass, F. Munschauer, R. Priore, P. Pullicino, B. Scherokman, B. Weistock-Guttman, R. Whitham (1997)
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosisNeurology, 49
-
B. Runmarker, O. Andersen (1993)
Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.Brain : a journal of neurology, 116 ( Pt 1)
-
D. Goodkin, R. Rudick (1996)
Multiple sclerosis : advances in clinical trial design, treatment, and future perspectives -
C. Confavreux, P. Saddier, J. Grimaud, T. Moreau, P. Adeleine, G. Aimard (1996)
Risk of cancer from azathioprine therapy in multiple sclerosisNeurology, 46
-
D. Paty, D. Li (1993)
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 43
-
N. Milligan, R. Newcombe, D. Compston (1987)
A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.Journal of Neurology, Neurosurgery & Psychiatry, 50
-
D. Archer, Paul Cuddon, David Lipsitz, Ian Duncan (1997)
Myelination of the canine central nervous system by glial cell transplantation: A model for repair of human myelin diseaseNature Medicine, 3
-
P. Lehmann, T. Forsthuber, A. Miller, E. Sercarz (1992)
Spreading of T-cell autoimmunity to cryptic determinants of an autoantigenNature, 358
-
J. Millar, C. Vas, M. Noronha, L. Liversedge, M. Rawson (1967)
Long-term treatment of multiple sclerosis with corticotrophin.Lancet, 2 7513
-
P. Yudkin, G. Ellison, A. Ghezzi, D. Goodkin, R. Hughes, K. McPherson, J. Mertin, C. Milanese (1991)
Overview of azathioprine treatment in multiple sclerosisThe Lancet, 338
-
J. Noseworthy, D. Paty, G. Ebers (1984)
Neuroimaging in multiple sclerosis.Neurologic clinics, 2 4
-
R. Rudick, J. Antel, C. Confavreux, G. Cutter, G. Ellison, J. Fischer, F. Lublin, Aaron Miller, J. Petkau, S. Rao, S. Reingold, K. Syndulko, Alan Thompson, Joy Wallenberg, B. Weinshenker, E. Willoughby (1997)
Recommendations from the national multiple sclerosis society clinical outcomes assessment task forceAnnals of Neurology, 42
-
C. Genain, K. Abel, N. Belmar, F. Villinger, D. Rosenberg, C. Linington, C. Raine, S. Hauser (1996)
Late Complications of Immune Deviation Therapy in a Nonhuman PrimateScience, 274
-
O. Stüve, N. Dooley, J. Uhm, J. Antel, G. Francis, V. Yong, Gary Williams (1996)
Interferon β‐1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase‐9Annals of Neurology, 40
-
H. Weiner, G. Mackin, E. Orav, D. Hafler, D. Dawson, Y. Lapierre, R. Herndon, J. Lehrich, S. Hauser, A. Turel, M. Fisher, G. Birnbaum, J. McArthur, R. Butler, M. Moore, B. Sigsbee, A. Safran (1993)
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosisNeurology, 43
-
F. Lhermitte, R. Marteau, E. Roullet (1984)
NOT SO BENIGN LONG-TERM IMMUNOSUPPRESSION IN MULTIPLE SCLEROSIS?The Lancet, 323
-
M. Bornstein, A. Miller, S. Slagle, M. Weitzman, H. Crystal, E. Drexler, M. Keilson, Arnold Merriam, S. Wassertheil-Smoller, V. Spada, W. Weiss, R. Arnon, I. Jacobsohn, D. Teitelbaum, M. Sela (1987)
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.The New England journal of medicine, 317 7
-
G. Ebers, Kim Kukay, D. Bulman, A. Sadovnick, G. Rice, C. Anderson, H. Armstrong, K. Cousin, R. Bell, W. Hader, D. Paty, S. Hashimoto, J. Oger, P. Duquette, S. Warren, T. Gray, P. O'Connor, A. Nath, A. Auty, L. Metz, G. Francis, J. Paulseth, T. Murray, W. Pryse-Phillips, R. Nelson, M. Freedman, D. Brunet, J. Bouchard, D. Hinds, N. Risch (1996)
A full genome search in multiple sclerosisNature Genetics, 13
-
Hong Lu, J. Riley, G. Babcock, M. Huston, George Stark, J. Boss, R. Ransohoff (1995)
Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48- kD DNA-binding protein, ISGF3-gammaThe Journal of Experimental Medicine, 182
-
J. Cohen, R. Grossman, J. Udupa, S. Samarasekera, Y. Miki, H. Hait, M. Grossman, CS Constantinescu, DL Kolson, F. González-Scarano, DH Silberberg, K. Johnson (1995)
Assessment of the efficacy of copolymer-1 in the treatment of MS by quantitative MRIJournal of Neuroimmunology, 56
-
G. Ebers, A. Sadovnick, N. Risch (1995)
A genetic basis for familial aggregation in multiple sclerosisNature, 377
-
L. Stone, J. Frank, P. Albert, C. Bash, Mary Smith, H. Maloni, H. McFarland (1995)
The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosisAnnals of Neurology, 37
-
R. Rudick, R. Ransohoff, R. Peppler, S. Medendorp, P. Lehmann, J. Alam (1996)
Interferon beta induces interleukin‐10 expression: Relevance to multiple sclerosisAnnals of Neurology, 40
-
L. Jacobs, D. Cookfair, R. Rudick, R. Herndon, J. Richert, A. Salazar, J. Fischer, D. Goodkin, C. Granger, J. Simon, J. Alam, D. Bartoszak, D. Bourdette, J. Braiman, C. Brownscheidle, M. Coats, S. Cohan, D. Dougherty, R. Kinkel, M. Mass, F. Munschauer, R. Priore, P. Pullicino, B. Scherokman, B. Weinstock-Guttman, R. Whitham (1996)
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 39
-
W. Sibley, C. Bamford, K. Clark (1985)
CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSISLancet (London, England), 325
-
A. Ben-nun, Z. Lando (1983)
Detection of autoimmune cells proliferating to myelin basic protein and selection of T cell lines that mediate experimental autoimmune encephalomyelitis (EAE) in mice.Journal of immunology, 130 3
-
Roy Beck, P. Cleary, J. Trobe, D. Kaufman, M. Kupersmith, D. Paty, C. Brown (1993)
The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group.The New England journal of medicine, 329 24
-
L. Wilkins (1996)
Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1bNeurology, 47
-
S. Kuokkanen, M. Sundvall, J. Terwilliger, P. Tienari, J. Wikström, R. Holmdahl, U. Pettersson, L. Peltonen (1996)
A putative vulnerability locus to multiple sclerosis maps to 5p14–p12 in a region syntenic to the murine locus Eae2Nature Genetics, 13
-
A. Mushlin, Cathleen Mooney, V. Grow, C. Phelps (1994)
The value of diagnostic information to patients with suspected multiple sclerosis. Rochester-Toronto MRI Study Group.Archives of neurology, 51 1
-
B. Weinshenker (1994)
Natural history of multiple sclerosisAnnals of Neurology, 36
-
L. Jacobs, D. Cookfair, R. Rudick, R. Herndon, J. Richert, A. Salazar, J. Fischer, D. Goodkin, C. Granger, J. Simon, L. Emrich, DM Bartoszak, D. Bourdette, J. Braiman, CM Brownscheidle, ME Coats, SL Cohan, DS Dougherty, R. Kinkel, MK Mass, F. Munschauer, R. Priore, PM Pullicino, BJ Scherokman, B. Weinstock-Guttman, R. Whitham (1995)
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patientsMultiple Sclerosis, 1
-
A. Sadovnick, G. Ebers (1995)
Genetics of multiple sclerosis.Neurologic clinics, 13 1
-
D. Wolinsky (1990)
Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double‐blinded, placebo‐controlled clinical trialAnnals of Neurology, 27
-
Bianca Weinstock-Guttman, R. Kinkel, Jeffrey Cohen, R. Ransohoff, K. Schwetz, D. Gogol, M. Namey, R. Rudick (1997)
TREATMENT OF FULMINANT MULTIPLE SCLEROSIS WITH INTRAVENOUS CYCLOPHOSPHAMIDEThe Neurologist, 3
-
J. Noseworthy, Baziel O'Brien, G. Engelen, Moses Rodriguez, B. Engelen (1994)
Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.Journal of Neurology, Neurosurgery & Psychiatry, 57
-
A. Rose, J. Kuzma, J. Kurtzke, W. Sibley, W. Tourtellotte, W. Dixon, J. Foley, N. Geschwind, C. Kane, R. Mackay, F. Mcdowell, L. Scheinberg, G. Schumacher, P. White (1968)
Cooperative study in the evaluation of therapy in multiple sclerosis; ACTH vs placebo in acute exacerbationsNeurology, 18
-
Rhys Williams, Alan Rigby, M. Airey, Mike Robinson, Helen Ford (1995)
Multiple sclerosis: it epidemiological, genetic, and health care impact.Journal of Epidemiology and Community Health, 49
-
C. Raine (1994)
Multiple sclerosis: immune system molecule expression in the central nervous system.Journal of neuropathology and experimental neurology, 53 4
-
G. Ellison, L. Myers, M. Mickey, M. Graves, W. Tourtellotte, K. Syndulko, M. Holevoet-Howson, C. Lerner, M. Frane, P. Pettier‐Jennings (1989)
A placebo‐controlled, randomized, double‐masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosisNeurology, 39
-
A. Thompson, C. Kennard, M. Swash, B. Summers, G. Yuill, D. Shepherd, S. Roche, G. Perkin, L. Loizou, R. Ferner, R. Hughes, M. Thompson, J. Hand (1989)
Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MSNeurology, 39
-
S. Brocke, Timo Veromaa, Irving Weissman, K. Gijbels, Lawrence Steinman (1994)
Infection and multiple sclerosis: a possible role for superantigens?Trends in microbiology, 2 7
-
D. Miller, P. Albert, F. Barkhof, G. Francis, Joseph Frank, S. Hodgkinson, F. Lublin, D. Paty, S. Reingold, J. Simon (1996)
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosisAnnals of Neurology, 39
-
D. Goodkin, R. Rudick, S. Medendorp, M. Daughtry, K. Schwetz, J. Fischer, C. Dyke (1995)
Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosisAnnals of Neurology, 37
-
R. Ransohoff, T. Hamilton, M. Tani, M. Stoler, H. Shick, J. Major, M. Estes, Dawn Thomas, V. Tuohy (1993)
Astrocyte expression of mRNA encoding cytokines IP‐10 and JE/MCP‐1 in experimental autoimmune encephalomyelitisThe FASEB Journal, 7
-
Dean Tippett, P. Fishman, H. Panitch (1991)
Relapsing transverse myelitisNeurology, 41
-
R. Beck (1995)
The Optic Neuritis Treatment Trial: Three-Year Follow-up ResultsArchives of Ophthalmology, 113
-
D. Paty, D. Goodkin, Alan Thompson, G. Rice (1996)
Guidelines for physicians with patients on IFN beta-1bNeurology, 47
-
F. Plum, J. Posner, B. Troy (1968)
Cerebral metabolic and circulatory responses to induced convulsions in animals.Archives of neurology, 18 1
-
D. Leppert, E. Waubant, M. Bürk, J. Oksenberg, S. Hauser (1996)
Interferon beta‐1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosisAnnals of Neurology, 40
-
Michael Nicolle, Bishwajit Nag, Somesh Sharma, Nicholas Willcox, Angela Vincent, David Ferguson, J. Newsom-Davis* (1994)
Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes.The Journal of clinical investigation, 93 4
-
D. Yao, Xia Liu, Lynn Hudson, H. Webster (1996)
Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis.Life sciences, 58 16
-
F. Lublin, S. Reingold (1996)
Defining the clinical course of multiple sclerosisNeurology, 46
-
J. Kurtzke (1983)
Rating neurologic impairment in multiple sclerosisNeurology, 33
-
MD Thompson, Mrcp Kermode, PhD Wicks, Dcr MacManus, Frcr Kendall, Fkcr Kingsley, Frcp McDonald, A. Thompson, D. Macmanus, B. Kendall, Kingsley Dpe, Mcdonald, David Thompson (1991)
Major differences in the dynamics of primary and secondary progressive multiple sclerosisAnnals of Neurology, 29
-
L. Durelli, M. Bongioanni, R. Cavallo, B. Ferrero, R. Ferri, M. Ferrio, G. Bradac, A. Riva, S. Vai, M. Geuna, L. Bergamini, B. Bergamasco (1994)
Chronic systemic high‐dose recombinant interferon alfa‐2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing‐remitting multiple sclerosisNeurology, 44
-
Youhai Chen, J. Inobe, H. Weiner (1995)
Induction of oral tolerance to myelin basic protein in CD8-depleted mice: both CD4+ and CD8+ cells mediate active suppression.Journal of immunology, 155 2
-
Min Yu, Justin Johnson, V. Tuohy (1996)
A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical diseaseThe Journal of Experimental Medicine, 183
-
N. Karin, D. Mitchell, S. Brocke, N. Ling, Lawrence Steinman (1994)
Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha productionThe Journal of Experimental Medicine, 180
-
B. Weinshenker (1996)
Clinical Outcome Measures for Multiple Sclerosis -
S. Hauser, D. Dawson, J. Lehrich, M. Beal, S. Kevy, R. Propper, J. Mills, H. Weiner (1983)
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.The New England journal of medicine, 308 4
-
D. Goodkin, R. Rudick, S. Medendorp, M. Daughtry, C. Dyke (1996)
Low-dose oral methotrexate in chronic progressive multiple sclerosisNeurology, 47
-
M. Swash, R. Rudick, D. Goodkin (1992)
Treatment of Multiple Sclerosis -
G. Ellison (1992)
Experimental Therapies for Multiple Sclerosis: Historical Perspective -
M. Filippi, M. Horsfield, S. Morrissey, D. MacManus, P. Rudge, W. Mcdonald, David Miller (1994)
Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosisNeurology, 44
-
Dennis Bourdette, R. Whitham, Y. Chou, William Morrison, J. Atherton, Christopher Kenny, D. Liefeld, G. Hashim, H. Offner, A. Vandenbark (1994)
Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides.Journal of immunology, 152 5
- Publisher
- The New England Journal of Medicine
- Copyright
- Copyright © 1997 Massachusetts Medical Society. All rights reserved.
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- DOI
- 10.1056/NEJM199711273372207
- pmid
- 9371858
- Publisher site
- See Article on Publisher Site
Abstract
Multiple sclerosis is a common disease of the central nervous system affecting approximately 1 million young adults, mostly women, worldwide.1 It is characterized by episodic neurologic symptoms that are often followed by fixed neurologic deficits, increasing disability, and medical, socioeconomic, and physical decline over a period of 30 to 40 years. For most of the 20th century, multiple sclerosis was considered untreatable. In 1982, the Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society of the United States sponsored the first international workshop on therapeutic trials.2 This workshop served to usher in an era of activism and optimism . . .
Journal
The New England Journal of Medicine – The New England Journal of Medicine
Published: Nov 27, 1997